The Adult Eczema Ladder, From Moisturizer to Biologic

What are the steps in adult eczema treatment?

Four levels, and the bottom one is permanent. Everything above it is added during flares and reduced afterwards, rather than replacing what sits below. Atopic dermatitis is driven by immune dysregulation together with a skin barrier that does not hold water or keep irritants out properly, and it belongs to the same atopic tendency as food allergy, asthma, and allergic rhinitis 1Ref 1National Institute of Allergy and Infectious Diseases (2024).Eczema (Atopic Dermatitis).The definitional framing used on this page: that atopic dermatitis involves immune dysregulation together with skin-barrier dysfunction, that it is chronic with a flaring course, and that it is associated with the atopic march alongside food allergy, asthma, and allergic rhinitis.. The ladder treats both halves of that: barrier care underneath, immune suppression on top.

You do not step off the floor when you step up. Barrier care is what makes every level above it work with less medicine.

Movement in both directions is normal. A person can spend six weeks at step three, come down to step one, and live there for a year. What the ladder is bad at is being climbed by guesswork, which is why the middle of this page is about how a step is judged to have failed.

The floor that never comes off

Moisturizers are not a consolation prize handed out before the real treatment. In a Cochrane review pooling 77 randomised trials, moisturizers improved eczema outcomes, lengthened the time between flares, reduced how many flares occurred, and — the finding that matters most to anyone worried about steroids — reduced the amount of topical corticosteroid needed when used alongside active treatment 2Ref 2van Zuuren EJ, Fedorowicz Z, Christensen R, et al. (2017).Emollients and moisturisers for eczema.That a Cochrane systematic review of 77 randomised trials found moisturizers improve eczema outcomes, prolong time to flare, reduce the number of flares, and reduce the amount of topical corticosteroid needed when combined with active treatment, and that it found no reliable evidence that one moisturizer is superior to another..

Across 77 randomised trials, moisturizers reduced flare frequency, prolonged time to flare, and cut the amount of topical steroid required 2Ref 2van Zuuren EJ, Fedorowicz Z, Christensen R, et al. (2017).Emollients and moisturisers for eczema.That a Cochrane systematic review of 77 randomised trials found moisturizers improve eczema outcomes, prolong time to flare, reduce the number of flares, and reduce the amount of topical corticosteroid needed when combined with active treatment, and that it found no reliable evidence that one moisturizer is superior to another..

The same review found no reliable evidence that any one moisturizer outperforms the others 2Ref 2van Zuuren EJ, Fedorowicz Z, Christensen R, et al. (2017).Emollients and moisturisers for eczema.That a Cochrane systematic review of 77 randomised trials found moisturizers improve eczema outcomes, prolong time to flare, reduce the number of flares, and reduce the amount of topical corticosteroid needed when combined with active treatment, and that it found no reliable evidence that one moisturizer is superior to another.. That is genuinely liberating information. It means the expensive tub is not buying a better outcome, and the correct product is largely the one a person will actually use several times a day for years — which usually means the one that does not sting, does not smell, and is affordable in the quantity this requires.

The quantity is the part most people get wrong. Eczema-strength moisturizing is measured in tubs rather than tubes, applied to the whole skin surface and not just the visible patches, and continued through the stretches when nothing looks wrong. Bathing practices sit alongside it in the topical guideline as part of the same maintenance layer 3Ref 3Sidbury R, Alikhan A, Bercovitch L, et al. (2023).Guidelines of care for the management of atopic dermatitis in adults with topical therapies.That AAD recommendations for topical management of atopic dermatitis in adults cover moisturizers and bathing as maintenance, and topical corticosteroids, the calcineurin inhibitors tacrolimus and pimecrolimus, crisaborole, and a topical JAK inhibitor as the anti-inflammatory step — the first-line topical tier of the ladder..

What the floor cannot do is put out an active flare on its own. Inflamed skin needs something anti-inflammatory, and applying more moisturizer to a raging patch is one of the commonest ways a person spends a month getting nowhere.

Step one: the anti-inflammatory creams

This step is a small family of drugs rather than one, and the differences between them are mostly about where on the body they can be used and for how long. Guideline recommendations for adults cover topical corticosteroids, the topical calcineurin inhibitors tacrolimus and pimecrolimus, crisaborole, and a topical JAK inhibitor 3Ref 3Sidbury R, Alikhan A, Bercovitch L, et al. (2023).Guidelines of care for the management of atopic dermatitis in adults with topical therapies.That AAD recommendations for topical management of atopic dermatitis in adults cover moisturizers and bathing as maintenance, and topical corticosteroids, the calcineurin inhibitors tacrolimus and pimecrolimus, crisaborole, and a topical JAK inhibitor as the anti-inflammatory step — the first-line topical tier of the ladder.. All of them are applied to affected skin; none of them replaces the moisturizer underneath.

Corticosteroids come in a range of potencies, and matching potency to site is the whole skill. Skin is thin on the face, the eyelids, and the folds, and thick on the palms and soles, so the same tube is wrong in both places.

Calcineurin inhibitors exist largely because of that problem. They are steroid-free, which makes them useful precisely where prolonged steroid use is a concern — around the eyes, on the face, in the folds — and their characteristic drawback is a burning sensation on application that often settles after the first week and drives people to quit before it does.

The newer non-steroids, crisaborole and the topical JAK inhibitor, add options at this level rather than a higher rung 3Ref 3Sidbury R, Alikhan A, Bercovitch L, et al. (2023).Guidelines of care for the management of atopic dermatitis in adults with topical therapies.That AAD recommendations for topical management of atopic dermatitis in adults cover moisturizers and bathing as maintenance, and topical corticosteroids, the calcineurin inhibitors tacrolimus and pimecrolimus, crisaborole, and a topical JAK inhibitor as the anti-inflammatory step — the first-line topical tier of the ladder.. They are still creams for a defined area, and they are still step one.

Topical calcineurin inhibitors are non-steroid anti-inflammatory creams that work on immune signalling in the skin rather than through steroid receptors.

The practical failure at this step is almost never the choice of molecule. It is quantity and duration: too little cream, spread too thin, stopped too early, restarted only once the flare is fully back.

The fear of steroid creams, and what the evidence does with it

It deserves a direct answer, because under-treating out of fear is more common in adult eczema than over-treating. The worry is real in origin: potent steroids used on thin skin for long unbroken stretches can thin it, and that is why guideline recommendations are written around potency, site, and duration rather than treating all steroid use as equivalent 3Ref 3Sidbury R, Alikhan A, Bercovitch L, et al. (2023).Guidelines of care for the management of atopic dermatitis in adults with topical therapies.That AAD recommendations for topical management of atopic dermatitis in adults cover moisturizers and bathing as maintenance, and topical corticosteroids, the calcineurin inhibitors tacrolimus and pimecrolimus, crisaborole, and a topical JAK inhibitor as the anti-inflammatory step — the first-line topical tier of the ladder..

The worry becomes harmful when it produces a pattern of using too little for too short a time, which leaves inflammation smouldering and eventually requires more medicine, not less. The Cochrane finding cuts directly across this: consistent moisturizer use reduced the amount of topical corticosteroid needed 2Ref 2van Zuuren EJ, Fedorowicz Z, Christensen R, et al. (2017).Emollients and moisturisers for eczema.That a Cochrane systematic review of 77 randomised trials found moisturizers improve eczema outcomes, prolong time to flare, reduce the number of flares, and reduce the amount of topical corticosteroid needed when combined with active treatment, and that it found no reliable evidence that one moisturizer is superior to another.. The route to less steroid runs through more moisturizer, not through rationing the steroid.

Using enough anti-inflammatory to actually clear a flare, then stopping, generally involves less total steroid than months of using too little.

There is a second pattern worth naming. Some people are advised to keep applying an anti-inflammatory on a reduced schedule to the sites that flare repeatedly, even after those sites look normal, rather than stopping the moment the skin clears. That approach treats the eczema that is still there but not yet visible, and it is a conversation worth having with a dermatologist rather than a decision to make alone — the schedule differs by person, by site, and by which agent is being used.

How do you know a step has failed?

The guideline language is more precise than it sounds. The threshold that unlocks systemic treatment is disease that is moderate-to-severe and inadequately controlled by topical therapy 4Ref 4Sidbury R, Davis DM, Alikhan A, et al. (2024).Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies.That AAD recommendations place phototherapy and systemic therapy — biologics including dupilumab, JAK inhibitors, and traditional systemic immunosuppressants — at the tier for adults with moderate-to-severe atopic dermatitis, and that this tier is framed around disease inadequately controlled by topical therapy.5Ref 5Simpson EL, Bieber T, Guttman-Yassky E, et al. (2016).Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis.That the SOLO 1 and SOLO 2 phase 3 randomised placebo-controlled trials showed dupilumab, an anti-interleukin-4-receptor antibody, improved signs, symptoms, itch, and quality of life in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical therapy — including the enrolment criterion this page uses to explain what unlocks the systemic step. — and the second half of that phrase is doing more work than the first. It is not asking whether the eczema is bad. It is asking whether an adequate trial of topical treatment, correctly chosen and actually carried out, failed to hold it.

That distinction is why so many people stall for years. Treatment-resistant eczema and under-treated eczema look identical from the outside, and only one of them justifies climbing. Before the step is called a failure, the honest questions are whether the potency matched the site, whether enough was applied, whether it was used for the full course rather than three days, and whether the moisturizer floor was ever really in place.

What a genuine failure looks like. Flares that return within days of stopping. Sleep broken by itch most nights. Skin that has not been clear for a stretch long enough to remember. Work, exercise, or intimacy being organised around the disease. Repeated courses of antibiotics for infected skin.

"Inadequately controlled by topical therapy" means an adequate trial was run and failed — not that the eczema is severe enough to skip one.

Writing this down before an appointment changes the appointment. A dermatologist deciding whether to escalate is reconstructing exactly this history, and a person who arrives with it is much harder to leave on a step that is not working.

Where phototherapy fits

Between the creams and the drugs that circulate through the whole body sits light. Phototherapy for eczema is covered in the same guideline as the systemic options, which is a useful signal about where it belongs: it is for disease too widespread or too persistent for topicals alone, but it is not a systemic immune drug 4Ref 4Sidbury R, Davis DM, Alikhan A, et al. (2024).Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies.That AAD recommendations place phototherapy and systemic therapy — biologics including dupilumab, JAK inhibitors, and traditional systemic immunosuppressants — at the tier for adults with moderate-to-severe atopic dermatitis, and that this tier is framed around disease inadequately controlled by topical therapy..

What it costs is time rather than side effects. Treatment happens in a cabinet in a clinic, on a repeating schedule, for a course of weeks — which means the real question for most adults is logistical. A person who cannot leave work several times a week for two months will not complete a course, and an unfinished course is not a fair test of the step.

Phototherapy usually fails for scheduling reasons rather than biological ones. Ask what the schedule is before agreeing to the referral.

Home units exist and are prescribed in some circumstances, which is worth raising directly if travel is the obstacle. So is the reverse conversation: if the schedule is impossible and the disease is severe, saying so is not a failure of commitment, and it may be the reason the discussion moves to the step above instead.

The systemic step: dupilumab and what came after

This is where treatment stops being applied to the skin and starts acting on the immune signalling that drives the disease. The guideline covers biologics, JAK inhibitors, and the older broad immunosuppressants at this level, for adults with moderate-to-severe disease 4Ref 4Sidbury R, Davis DM, Alikhan A, et al. (2024).Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies.That AAD recommendations place phototherapy and systemic therapy — biologics including dupilumab, JAK inhibitors, and traditional systemic immunosuppressants — at the tier for adults with moderate-to-severe atopic dermatitis, and that this tier is framed around disease inadequately controlled by topical therapy.. The three are not interchangeable, and they are not equivalent in what they ask of the person taking them.

Dupilumab, an antibody against the interleukin-4 receptor, is the one most adults are offered first. Two phase 3 trials, SOLO 1 and SOLO 2, tested it against placebo in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical therapy, and it improved the signs of the disease, the symptoms, the itch, and quality of life 5Ref 5Simpson EL, Bieber T, Guttman-Yassky E, et al. (2016).Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis.That the SOLO 1 and SOLO 2 phase 3 randomised placebo-controlled trials showed dupilumab, an anti-interleukin-4-receptor antibody, improved signs, symptoms, itch, and quality of life in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical therapy — including the enrolment criterion this page uses to explain what unlocks the systemic step.. That last pair matters more than it looks: itch and quality of life were measured as outcomes in their own right, not inferred from how the skin looked.

What differs across this step. The biologics act on a specific signalling pathway and are injected. The JAK inhibitors are taken by mouth, act faster in many people, and carry the monitoring and the boxed labelling that come with the class 4Ref 4Sidbury R, Davis DM, Alikhan A, et al. (2024).Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies.That AAD recommendations place phototherapy and systemic therapy — biologics including dupilumab, JAK inhibitors, and traditional systemic immunosuppressants — at the tier for adults with moderate-to-severe atopic dermatitis, and that this tier is framed around disease inadequately controlled by topical therapy.. The older immunosuppressants suppress immunity broadly and require blood monitoring for organ effects. Which of these fits depends on other conditions, on how fast control is needed, and on what a person can realistically keep up with.

None of it removes the floor. Moisturizer continues underneath all of it, and most people at this step still use a topical anti-inflammatory for the patches that persist.

The eczemas that do not follow this ladder

This page describes atopic dermatitis in adults. Several conditions get called eczema, look like it, and behave differently enough that following this sequence wastes months. The most consequential mismatch is contact dermatitis: skin inflamed by something it is touching does not respond durably to any step of this ladder while the exposure continues, and the treatment is identifying the trigger, which usually means patch testing rather than a stronger cream.

Dyshidrotic eczema treatment is its own discussion — deep, intensely itchy blisters on palms and the sides of fingers follow a different rhythm and respond differently to the same agents. Nummular eczema forms coin-shaped plaques that are frequently mistaken for ringworm and treated with an antifungal for weeks before anyone reconsiders.

The adjacent disease that causes the most confusion is psoriasis, and the two have entirely separate guideline sets. Psoriasis biologics are grouped by different targets — the tumour necrosis factor, interleukin-17, interleukin-23, and interleukin-12/23 classes — with their own efficacy and safety monitoring recommendations 6Ref 6American Academy of Dermatology; National Psoriasis Foundation (2019).Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics.That psoriasis has its own separate biologic guideline, organised around tumour necrosis factor, interleukin-17, interleukin-23, and interleukin-12/23 inhibitors with their own efficacy and safety-monitoring recommendations — cited here to mark that the psoriasis and eczema systemic tiers are distinct and not interchangeable.. The psoriasis treatment ladder is a genuinely different climb, and a biologic that transforms one disease can do nothing at all for the other.

If a well-run step produces no change whatsoever, the question to revisit is the diagnosis — not the potency.

Atopic dermatitis itself is a chronic disease with a flare-and-remission course 1Ref 1National Institute of Allergy and Infectious Diseases (2024).Eczema (Atopic Dermatitis).The definitional framing used on this page: that atopic dermatitis involves immune dysregulation together with skin-barrier dysfunction, that it is chronic with a flaring course, and that it is associated with the atopic march alongside food allergy, asthma, and allergic rhinitis.. Steps are meant to be climbed and descended repeatedly. A ladder that only ever goes one direction is usually a sign that something below it was never properly in place.